Archives of Current Medical Research 2021-01-29T23:49:04+03:00 Hasan Serdar Öztürk, MD, PhD. Professor of Medical Biochemistry Open Journal Systems <p><strong><span style="vertical-align: inherit;"><span style="vertical-align: inherit;">E-ISSN:</span></span></strong><span style="vertical-align: inherit;"><span style="vertical-align: inherit;"> 2717-9788</span></span></p> <p><span style="vertical-align: inherit;"><strong><span style="vertical-align: inherit;">Abstracting and Indexing:</span></strong><span style="vertical-align: inherit;"> EuroPub, Directory of Research Journal Indexing, Eurasian Scientific Journal Index, Scientific Indexing Services (SIS), CiteFactor, Asos İndeks, TurkMedline Google Scholar, Crossref</span></span></p> <p>Archives of Current Medical Research (ACMR) is an international, peer-reviewed, open-access scientific journal for publication of original medical, pre-clinical and clinical research, case reports, reviews and letters about all areas of medicine, dentistry and related medical disciplines. Each manuscript submitted to ACMR is primarily taken into editorial review. After that, the peer-review process begins for the selected manuscripts. ACMR uses double-blind review concealing author names from the reviewers and vice versa throughout the reviewing process. There are no submission or publication charges to submit your manuscript to ACMR. Manuscripts must be submitted electronically using the following link:</p> <p><strong>There are no submission or publication charges to submit your manuscript. </strong></p> <p>The authors have to submit their ORCID numbers during the submission.</p> <p>This journal provides instant open access to all content, bearing in mind the fact that presenting research free to the public supports a greater global exchange of knowledge.</p> <p>Articles "published" online are freely available to the public on the Internet.</p> <p><strong><em>The authors are responsible for the accuracy of the references. Key the references (double-spaced) at the end of the manuscript. EndNote users can access a direct download of the updated ACMR Publications style at </em></strong><a href=""><strong><em></em></strong></a></p> <p><span style="vertical-align: inherit;"><span style="vertical-align: inherit;"><span style="vertical-align: inherit;"><span style="vertical-align: inherit;"> <strong><a href=""><img src="" alt="" width="142" height="67" /></a> </strong> </span></span></span></span></p> The Real Life Data for Glecaprevir/Pibrentasvir: A Single-Center Study 2020-12-29T13:59:08+03:00 Fatma Çölkesen Arzu Tarakçı Fatma Kacar Esma Eroğlu Şule Özdemir Armağan <p><strong>Background:</strong> Licensing of next-generation direct-acting antiviral agents (DAA) has revolutionized the treatment of Hepatitis C Virus (HCV) infection. These agents are important due to their high virological efficacy, high resistance barrier, short duration of treatment, and rare serious side effects. The purpose of our study was to present real-life data of chronic hepatitis C (CHC) infected patients with genotypes 2 and 3 who were treated with glecaprevir/pibrentasvir regimen.<br /><strong>Methods:</strong> Glecaprevir/pibrentasvir treatment was initiated in 127 patients infected with CHC genotype 2 and 3. Patients received glecaprevir/pibrentasvir (100 mg/40 mg) orally in the form of three tablets once a day as per recommendations of the Republic of Turkey, Ministry of Health. In the assessments of patients at the time of diagnosis and following DAA use, virological response criteria HCV-RNA value was &lt;25 IU/ml.<br /><strong>Results:</strong> 127 patients were included in the study. The mean age of the patients was 27 ± 6, and 125 patients (98.4%) were male. 118 patients (92.9%) had a history of intravenous drug use, and 78 patients (61.4%) were convicts. 83.6% (n:106) of the patients were genotype 3, 15% (n:19) genotype 2, 0.7% (n:1) genotype 1+3, and 0.7% (n:1) genotype 3+4. The mean liver fibrosis stage was 1.7±0.8 and histological activity index was 7.9±2.7. 99.2% (n:126) of the patients achieved virological response and sustained virological response (SVR)-12, and only 1 patient did not achieve end-of-treatment response and SVR-12.<br /><strong>Conclusion:</strong> An effective, well-tolerated, oral and short-term treatment for patients infected with CHC genotypes 2 and 3 is currently possible with glecaprevir/pibrentasvir.</p> 2021-01-29T00:00:00+03:00 Copyright (c) 2021 Archives of Current Medical Research Intra-articular Methylprednisolone Injection for Advanced Knee Osteoarthritis in Geriatric Patient Population 2020-12-02T11:08:55+03:00 Ali Yüce Niyazi İğde Tahsin Olgun Bayraktar Mustafa Yerli Ali Çağrı Tekin Mehmet Kürşat Bayraktar Hakan Gürbüz <p><strong>Background:</strong> We aimed to investigate the effect of intra-articular methylprednisolone injection on pain and functional outcomes and the number of outpatient clinic admissions in patients with advanced knee osteoarthritis in the geriatric age group.</p> <p><strong>Method:</strong> The files of 78 patients over the age of 65 who were administered intra-articular methylprednisolone injection with the diagnosis of primary gonarthrosis between 2018 and 2020 were analyzed retrospectively.&nbsp; Age, gender, and affected side of the patients were recorded. The number of outpatient clinic admissions, VAS and Womac scores before and after injection were evaluated statistically.</p> <p><strong>Results:</strong> Of the patients, 18 were male (24.7%) and 55 were female (75.3%). The mean age was 74.95±7.11 years. The values of the patients' WOMAC and VPS scores at the 1st and 3rd months were significantly lower than the pre-injection period. Compared to the number of outpatient visits in the 6-month period before injection, the decrease in the number of outpatient visits in the 6-month period after injection was statistically significant. A strong positive correlation was found between the number of outpatient visits before injection and the first VPS score.</p> <p><strong>Conclusions:</strong> In geriatric patients with advanced-stage osteoarthritis who do not accept total knee arthroplasty, intra-articular methylprednisolone injection may be a feasible method that reduces pain and the number of outpatient visits in the short term.</p> 2021-01-30T00:00:00+03:00 Copyright (c) 2021 Archives of Current Medical Research Suzuki Frame Results in the Treatment of Comminuted Phalanx Fractures 2020-12-24T15:28:12+03:00 Mehmet Cenk Turgut Serdar Toy <p><strong>Background:</strong> Comminuted fracture of the PIP joint is one of the most challenging fractures to be treated in hand surgery practice. The pins and rubber traction frame is an easy method to perform for these fractures. This study aimed to present the treatment stages of patients who had PIP joint fractures-dislocations with the pins and rubber traction frame and the functional results of patients.<br /><strong>Methods:</strong> The results of eight patients with fracture-dislocations of the PIP joint between 2016 and 2019 were retrospectively analyzed. Age and gender of patients, time between trauma and surgery, postoperative follow-up periods, affected area on the joint surface, postoperative complications, range of motion of PIP and DIP joints, affected finger, and the causes of the trauma were recorded.<br /><strong>Results:</strong> Five (62.5%) patients were male, and three (37.5%) patients were female in this study. The mean age of the patients was 28.50 ± 3.42 years. The mean range of motion of the PIP joint examined in the postoperative 12th month was 4.88° to 86.25°. In the same period, the mean range of motion of the DIP joint of the patients was 4.38° to 86.25°. We obtained union in all patients. Malunion or nonunion and osteomyelitis were not seen in any patients.<br /><strong>Conclusions:</strong> The pins and rubber traction frame is a method that can be used safely and effectively in fractures of the phalanx joints that are difficult, comminuted, and involving the joint.</p> 2021-01-29T00:00:00+03:00 Copyright (c) 2021 Archives of Current Medical Research Antioxidant Efficacy of Hypericum Perforatum L. on 7,12-Dimethylbenzanthracene-Applied Rat Tongue Tissues 2021-01-12T22:31:52+03:00 Dilara Nur Şengün Gülşah Demirci İnci Rana Karaca <p><strong>Background:</strong> Hypericum species have chemopreventive and antioxidant effects which have been described in the past. However, Hypericum perforatum L. extract has not been the subject of any in vivo chemoprevention studies. The purpose of this study was to investigate the effects of H. perforatum L. extract on the oxidant-antioxidant system in 7,12 dimethylbenzantracene applied tongue tissues of rats.<br /><strong>Methods:</strong> Thirty male Wistar rats were divided into four groups. Control group: only paraffin, DMBA group: only 7,12-dimethylbenzantracene, HP+DMBA group: 7,12 dimethylbenzantracene and H. perforatum L. extract and HP group: only H. perforatum L. extract application to the oral mucosa. After a 16-week study period, animals were sacrificed and tongue samples were taken. Superoxide dismutase, catalase, glutathione peroxidase enzyme activities, and malondialdehyde and total antioxidant status levels were measured.<br /><strong>Results:</strong> HP+DMBA group revealed significant differences with regard to catalase and superoxide dismutase enzymes compared to control, DMBA and HP groups (Catalase: p = 0.019, 0.019, 0.000, respectively; Superoxide dismutase: p = 0.001, 0.012, 0.009, respectively). Parallel to this data, total antioxidant status value in the same group was decreased with regard to other groups. Glutathione peroxidase enzyme activity and malondialdehyde levels did not demonstrate any significant differences among groups.<br /><strong>Conclusions:</strong> H. perforatum L. extract did not reveal any significant evidence that indicates an antioxidant effect. Moreover, antioxidant enzymes (catalase and superoxide dismutase) were believed to be suppressed by a by-product of H. perforatum L. and 7,12 dimethylbenzantracene reaction in the HP+DMBA group.</p> 2021-01-29T00:00:00+03:00 Copyright (c) 2021 Archives of Current Medical Research Are Patients With Diabetes Mellitus at Increased Risk of COVID-19 Infection? 2020-12-17T14:20:32+03:00 Mehmet Sözen Fatma Çölkesen Şevket Arslan Fatih Çölkesen Melia Karaköse İbrahim Erayman Soner Demirbaş Turgut Teke <p><strong>Background:</strong> The aim of this study was to examine the clinical course and outcomes of patients with diabetes mellitus (DM) with coronavirus disease-2019 (COVID-19).<br /><strong>Methods:</strong> This retrospective, single-center study included 185 adult patients diagnosed with COVID-19. All patients were separated into 4 groups. Group 1(n=79): patients with no accompanying disease, Group 2 (n=14): patients with only DM, Group 3 (n=31): patients with comorbid disease(s) including DM, Group 4 (n=61): patients with comorbid disease(s) without DM. Data about COVID-19 management and outcome were obtained from the medical records of the patients. COVID-19 was confirmed by real-time polymerase chain reaction (RT-PCR) from throat swab samples. All patients underwent chest x-rays or chest computed tomography.<br /><strong>Results:</strong> 185 patients diagnosed with COVID-19 were evaluated. The COVID-19 prognoses of the patients were classified as good, moderate and poor. No statistically significant difference was determined between the groups in terms of COVID-19 prognosis (p&gt;0.05). While the rate of DM patients with a good prognosis was 20.4%, the DM patient rate increased up to 40% among moderate or poor prognosis patients. A statistically significant difference was observed between blood glucose levels and mortality (p: 0.008). Mortality due to COVID-19 pneumonia developed in 15 (8.1%) patients. Mortality increase was mostly encountered in the group with DM and accompanying comorbidities. It was observed that ACEI / ARB use had no effect on mortality.<br /><strong>Conclusions:</strong> Although the study results do not show a statistically significant effect of DM on the prognosis of COVID-19 patients, the higher rate of DM patients in the group with poor prognosis suggests that it may affect the severity of COVID-19. These results may be useful for clinicians in the management of DM patients with COVID-19.</p> 2021-01-29T00:00:00+03:00 Copyright (c) 2021 Archives of Current Medical Research The Predictive Role of the CHADS-VASc Score on Reduced Left Ventricular Ejection Fraction in Patients with Acute Coronary Syndrome 2021-01-08T14:06:40+03:00 Uğur Küçük <p><strong>Background:</strong> Reduced left ventricular systolic function is associated with significant mortality and morbidity in patients with the acute coronary syndrome (ACS). Predicting which patients may go on to develop heart failure (HF) with optimal treatment is thus likely to be effective in reducing mortality and morbidity. This study aims to evaluate the role of the CHA2DS2-VASc score in predicting reduced left ventricular ejection fraction (LVEF) in patients with ACS.<br /><strong>Methods:</strong> 202 patients diagnosed with the ACS participated in the study. Coronary angiography (CAG) was performed on all patients. The LVEF values of the patients before and three months after discharge were evaluated by transthoracic echocardiogram (TTE). Group 1 consisted of patients with LVEF values below 50% at the third month, while Group 2 consisted of those with LVEF values of 50% and above.<br /><strong>Results:</strong> The mean age of the patients was 62 ± 12 years, and 142 of the patients were male. The LVEF values in the third month were 55.58 ± 0.24 in Group 1 and 42.07 ± 0.86 in Group 2 (p&lt;0.001). While the mean CHA2DS2-VASc score was 0.86 ± 0.78 in Group 1, it was 1.78 ± 0.87 in Group 2 (p&lt;0.001). Multiple regression analysis showed that the CHA2DS2-VASc score had an independent relationship in predicting the LVEF values in patients with ACS (Odds ratio [OR] 3.179, 95% CI 1.972-5.124, p&lt;0.001). CHA2DS2- VASc scores above 1.5 can be used as a predictor for decreased left ventricular systolic function in patients with ACS with 53% sensitivity and 80% specificity.<br /><strong>Conclusion:</strong> The CHA2DS2-VASc score is a simple and easy parameter that can be used to predict decreased and preserved left ventricular systolic functions in patients with ACS.</p> 2021-01-29T00:00:00+03:00 Copyright (c) 2021 Archives of Current Medical Research Use of Vitamin, Mineral and Supporting Products in Children in Adana 2020-12-30T21:23:05+03:00 Betül Cansever Akay Adnan Barutçu Nurdan Evliyaoğlu Eray Akay <p><strong>Background:</strong> To determine the frequency, methods and families’ knowledge about vitamins, minerals and supplementary products in children.<br /><strong>Methods:</strong> A questionnaire form was applied by face-to-face interviews with a total of 300 parents with children under the age of 5 who applied to the University Hospital, Training and Research Hospital and randomly selected family health centers in Adana. The demographic characteristics of the participants, their level of knowledge about preventive medication and supportive products, how they used them, and who suggested starting them were evaluated.<br /><strong>Results:</strong> The mean age of the children included in the study was 24.3±18.1 months. The correct use rates of iron and vitamin D by the parents were 60.7% and 83.3%, respectively. 147 of the parents (49%) used at least one supportive product to their children, and multivitamin (12.5%), molasses (8.3%), cumin (7.3%), honey (6.3%), fish oil (6.3%) was observed to be among the preferred products. It was found that supportive products were most frequently started due to growth and development retardation (27.7%) with the suggestions of neighbors-close relatives (45.8%) and doctors (30.7%).<br /><strong>Conclusions:</strong> Iron and vitamin D preparations are distributed free of charge in our country; however, we believe that the correct usage rates are not at the desired level, and more training and information should be given to healthcare professionals and parents in terms of compliance with prophylaxis and correct use. Although there is not enough data in our country regarding use of supportive products, more reliable results can be obtained with more comprehensive studies.</p> 2021-01-29T00:00:00+03:00 Copyright (c) 2021 Archives of Current Medical Research The Virology, Immunity and Vaccine Development of SARS-CoV-2 2021-01-28T09:46:33+03:00 Sidre Erganiş Gülendam Bozdayı <p>Since the last months of 2019, the COVID-19 pandemic caused by SARS-CoV-2, a brand new coronavirus, catches our attention on our agenda as it harms economic and socio-cultural structures almost all around the world. For the elimination of SARS-CoV-2, there has to be an effective and sufficient immune response that includes innate and adaptive immunity against the virus. Also, this immunity should help us to prevent and control the infection. However, there are some complications about our body’s response to this virus: Hyperactivation of the immune response can cause tissue damage and organ failures. On the other hand, immunodeficiency is one of the major obstacles to the elimination of the virus. Type I IFN response is essential for COVID-19 disease. Some of the SARS-CoV-2 infection pathogenesis is caused by delay, deficiency, or inhibition of IFN release. The infection can be limited if type I IFN is secreted early and adequately. The overproduction of pro-inflammatory cytokines (such as IL-1, IL-6, and TNFα), neutrophilia, and lymphopenia is associated with COVID-19 disease severity and mortality in patients. Our current understanding of SARS-CoV-2 immunity is still limited. Further clarification of the immunopathogenesis of COVID-19 disease will guide us in both diagnosis and treatment. It will also shed light on new drugs and vaccine studies. Therefore, extensive researches on the host immune response against SARS-CoV-2 are still necessary.</p> 2021-01-29T00:00:00+03:00 Copyright (c) 2021 Archives of Current Medical Research Phytocontact Dermatitis Due to Ranunculus Kotschyi Boiss : Adverse Effect for Artralgia Treatment 2020-11-30T11:20:33+03:00 Gültekin Kadı Muhammed Enes Durak Begüm Öktem Ahmet Demircan Ayfer Keleş <p>There has been a great variety of cases relating to herbal therapies across the world. Some of them do not have any risks, whereas some others may result in severe complications. Ranunculus kotschyi (buttercup) is a wild annual plant belonging to Ranunculaceae family. Many phytodermatitis cases associated with the members of the Ranunculaceae family have been reported. In this case report, we present a 60-year-old female patient suffering from irritant phytodermatitis secondary to topical use of Ranunculus kotschyi.</p> 2021-01-29T00:00:00+03:00 Copyright (c) 2021 Archives of Current Medical Research A Rare Clinical Presentation Caused by Atrial Myxoma: Right Heart Failure 2020-12-04T11:42:45+03:00 Ferhat Dindaş İdris Buğra Cerik Emin Koyun Okan Onur Turgut <p><span style="vertical-align: inherit;"><span style="vertical-align: inherit;">Birincil kalp tümörleri nadiren görülür. </span><span style="vertical-align: inherit;">Bu tümör grubuna dahil olan miksomalar, kalbin en sık görülen primer benign neoplazmalarıdır ve bunların yaklaşık% 75-80'i sol atriyumda bulunur. </span><span style="vertical-align: inherit;">Olgumuzda son üç ayda artan nefes darlığı, göğüste ağrı ve bacaklarda şişlik şikayetleri olan 72 yaşında kadın hasta. </span><span style="vertical-align: inherit;">Klinik olarak sağ kalp yetersizliği bulguları gösteren, sağ atriyumu neredeyse tamamen tıkayan ve sağ ventriküle uzanan ekokardiyografik incelemeye göre interatriyal septuma yapışık 80x60x15 mm boyutlarında sağ atriyumda miksomalı bir olgu sunuyoruz. </span><span style="vertical-align: inherit;">Ekokardiyografide de çıkan aort anevrizması saptandı. </span><span style="vertical-align: inherit;">Kalp boşluklarını tıkayan sağ atriyal kitlenin ameliyatla çıkarılmasına rağmen, &nbsp;&nbsp;</span></span></p> 2021-01-30T00:00:00+03:00 Copyright (c) 2021 Archives of Current Medical Research